Pharmacoresistant epilepsy: From pathogenesis to current and emerging therapies

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 7, 2010, Pages 457-467

  Pati, Sandipan ^a   Alexopoulos, Andreas V ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

CORPUS CALLOSUM; DRUG EFFECT; DRUG RESISTANCE; ELECTROSTIMULATION; EPILEPSY; GENETICS; HEMISPHERECTOMY; HIPPOCAMPUS; HUMAN; KETOGENIC DIET; LIFESTYLE; PHARMACOGENETICS; REVIEW; RISK ASSESSMENT; TEMPORAL LOBECTOMY; TREATMENT FAILURE; UNITED STATES; VAGUS NERVE STIMULATION;

ANTERIOR TEMPORAL LOBECTOMY; ANTICONVULSANTS; CORPUS CALLOSUM; DRUG RESISTANCE; ELECTRIC STIMULATION; EPILEPSY; HEMISPHERECTOMY; HIPPOCAMPUS; HUMANS; KETOGENIC DIET; LIFE STYLE; OHIO; PHARMACOGENETICS; RISK ASSESSMENT; TREATMENT FAILURE; VAGUS NERVE STIMULATION;

EID: 77954668304     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.09061     Document Type: Review

References (50)

1. Siegel AM. Presurgical evaluation and surgical treatment of medically refractory epilepsy. Neurosurg Rev 2004; 27:1-18.
2. Murray MI, Halpern MT, Leppik IE . Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996; 23:139-148.
3. Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 1998; 39:776-786.
4. Chapell R, Reston J, Snyder D, Treadwell J, Treager S, Turkelson C. Management of treatment-resistant epilepsy. Evid Rep Technol Assess (Summ) 2003 Apr;(77):1-8.
5. Nei M, Bagla R. Seizure-related injury and death. Curr Neurol Neurosci Rep 2007; 7:335-341.
6. Langan Y, Nashef L, Sander JW. Case-control study of SUDEP. Neurology 2005; 64:1131-1133.
7. Sperling MR, Feldman H, Kinman J, Liporace JD, O'Connor MJ. Seizure control and mortality in epilepsy. Ann Neurol 1999; 46:45-50.
8. B erg AT. Understanding the delay before epilepsy surgery: who develops intractable focal epilepsy and when? CNS Spectr 2004; 9:136-144.
9. Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs 1998; 10:171-179.
10. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314-319.
11. Gumnit RJ, Walczak TS; National Association of Epilepsy Centers. Guidelines for essential services, personnel, and facilities in specialized epilepsy centers in the United States. Epilepsia 2001; 42:804-814.
12. Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM 1999; 92:15-23.
13. Schuele SU, Lüders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008; 7:514-524.
14. Engel J, Jr, Burchfiel J, Ebersole J, et al. Long-term monitoring for epilepsy. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1993; 87:437-458.
15. Kanner AM, Morris HH, Lüders H, et al. Supplementary motor seizures mimicking pseudoseizures: some clinical differences. Neurology 1990; 40:1404-1407.
16. Alexopoulos AV, Dinner DS. Focal motor seizures, epilepsia partialis continua, and supplementary sensorimotor seizures. In: Wyllie E, Gupta A, Lachhwani DK, editors. The Treatment of Epilepsy: Principles & Practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2006:257-277.
17. French JA. Refractory epilepsy: clinical overview. Epilepsia 2007; 48(suppl 1):3-7.
18. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999; 34:109-122.
19. Berg AT, Langfitt J, Shinnar S, et al. How long does it take for partial epilepsy to become intractable? Neurology 2003; 60:186-190.
20. Berg AT, Vickrey BG, Testa FM, et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 2006; 60:73-79.
21. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006; 47:1253-1284.
22. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6:591-602.
23. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348:1442-1448.
24. G ranata T, Marchi N, Carlton E, et al. Management of the patient with medically refractory epilepsy. Expert Rev Neurother 2009; 9:1791-1802.
25. Marchi N, Hallene KL, Kight KM, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2004; 2:37.
26. Oby E, Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006; 47:1761-1774.
27. Schmidt D, Löscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr 2009; 9:47-52.
28. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006; 129:18- 35.
29. Löscher W, Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res 2002; 50:3-16.
30. Sirven J, Whedon B, Caplan D, et al. The ketogenic diet for intractable epilepsy in adults: preliminary results. Epilepsia 1999; 40:1721-1726.
31. Fisher RS, Handforth A. Reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999; 53:666-669.
32. Hallböök T, Lundgren J, Stjernqvist K, Blennow G, Strömblad LG, Rosén I. Vagus nerve stimulation in 15 children with therapy resistant epilepsy; its impact on cognition, quality of life, behaviour and mood. Seizure 2005; 14:504-513.
33. Holmes MD, Silbergeld DL, Drouhard D, Wilensky AJ, Ojemann LM. Effect of vagus nerve stimulation on adults with pharmacoresistant generalized epilepsy syndromes. Seizure 2004; 13:340-345.
34. Murphy JV, Torkelson R, Dowler I, Simon S, Hudson S. Vagal nerve stimulation in refractory epilepsy: the first 100 patients receiving vagal nerve stimulation at a pediatric epilepsy center. Arch Pediatr Adolesc Med 2003; 157:560-564.
35. Alexopoulos AV, Najm IM. Neurosurgical management of focal epilepsies in adults. In: Panayiotopoulos CP,et al, editors. Focal Epilepsies: Seizures, Syndromes and Management. Oxford, UK: Medicinae; 2009:204- 220.
36. Wieser HG; ILAE Commission on Neurosurgery of Epilepsy. ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 2004; 45:695-714.
37. Engel J, Jr. Surgery for seizures. N Engl J Med 1996; 334:647-652.
38. Engel J Jr, Wiebe S, French J, et al; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society; American Association of Neurological Surgeons. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003; 60:538-547.
39. Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345:311-318.
40. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51:1256-1262.
41. Awad IA , Rosenfeld J, Ahl J, Hahn JF, Lüders H. Intractable epilepsy and structural lesions of the brain: mapping, resection strategies, and seizure outcome. Epilepsia 1991; 32:179-186.
42. Cascino GD. Surgical treatment for extratemporal epilepsy. Curr Treat Options Neurol 2004; 6:257-262.
43. González-Martínez JA, Gupta A, Kotagal P, et al. Hemispherectomy for catastrophic epilepsy in infants. Epilepsia 2005; 46:1518-1525.
44. Wyllie E. Surgery for catastrophic localization-related epilepsy in infants. Epilepsia 1996; 37(suppl 1):S22- S25.
45. Tanriverdi T, Olivier A, Poulin N, Andermann F, Dubeau F. Long-term seizure outcome after corpus callosotomy: a retrospective analysis of 95 patients. J Neurosurg 2009; 110:332-342.
46. Asadi-Pooya AA, Sharan A, Nei M, Sperling MR. Corpus callosotomy. Epilepsy Behav 2008; 13:271-278.
47. Spencer SS, Schramm J, Wyler A, et al. Multiple subpial transection for intractable partial epilepsy: an international meta-analysis. Epilepsia 2002; 43:141-145.
48. Alexopoulos AV, Gonugunta V, Yang J, Boulis NM. Electrical stimulation and gene-based neuromodulation for control of medically-refractory epilepsy. Acta Neurochir Suppl 2007; 97:293-309.
49. Detlev B. Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 2007; 5:115-125.
50. Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 2002; 16:579-593.